Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus. As an investigational therapy, obexelimab has not been approved for commercial use.

The company advances its programs through clinical development and collaborations with biotechnology and pharmaceutical partners. Zenas BioPharma is headquartered in Waltham, Massachusetts, and its development activities are focused primarily on clinical trials in the United States and other international markets.

Key Stats

• Today's Range: $29.53 to $33.09
• 50-Day Range: $28.24 to $33.77
• 52-Week Range: $13.50 to $44.60
• Volume: 525,075 shs
• Average Volume: 822,559 shs
• Market Capitalization: $1.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.71
• Consensus Rating: Moderate Buy

Zenas BioPharma Stock Analysis - MarketRank™

Zenas BioPharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 549th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Zenas BioPharma has a consensus price target of $45.71, representing about 53.3% upside from its current price of $29.82.

Amount of Analyst Coverage

Zenas BioPharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zenas BioPharma are expected to grow in the coming year, from ($5.81) to ($4.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zenas BioPharma is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zenas BioPharma is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zenas BioPharma has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.02% of the float of Zenas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Zenas BioPharma has a short interest ratio ("days to cover") of 14.18, which indicates bearish sentiment.

Change versus previous month

Short interest in Zenas BioPharma has recently increased by 0.37%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zenas BioPharma does not currently pay a dividend.

Dividend Growth

Zenas BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

Zenas BioPharma has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Zenas BioPharma this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Zenas BioPharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/23/2026
• Study update: 9/29/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: zenasbio.com
• Phone: (857) 271-2954
• Fax: N/A
• Employees: 167
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Zenas BioPharma: $45.71
• High Price Target: $55.00
• Low Price Target: $32.00
• Potential Upside/Downside: +54.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.74 million
• Net Margins: N/A
• Pretax Margin: -48,416.40%
• Return on Equity: -122.45%
• Return on Assets: -58.04%

Debt

• Debt-to-Equity Ratio: 1.57
• Current Ratio: 9.93
• Quick Ratio: 9.93

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 1,931.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.51 per share
• Price / Book: 6.57

Miscellaneous

• Outstanding Shares: 65,177,000
• Free Float: 50,838,000
• Market Cap: $1.93 billion
• Optionable: N/A
• Beta: -1.04